2024
Incidence of bacterial blood stream infections in patients with acute GVHD
Wallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem M, MacMillan M, Kitko C, Pidala J, Spellman S, Lee S, Alousi A. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplantation 2024, 1-6. PMID: 39420192, DOI: 10.1038/s41409-024-02426-9.Peer-Reviewed Original ResearchBacterial bloodstream infectionsHematopoietic stem cell transplantationAcute GVHDNon-relapse mortalityGrade II-IV acute GVHDAllogeneic hematopoietic stem cell transplantationGrade III/IV acute GVHDBacterial blood stream infectionsAssociated with worse survivalStem cell transplantationBlood stream infectionsHigh-risk populationGVHD treatmentNeutrophil engraftmentBloodstream infectionsWorse survivalCell transplantationGI involvementOrgan involvementPost-transplantationPost-engraftmentRisk populationHigh riskPatientsGVHDP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacyReal-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, Perales M, Munoz J, Fingrut W, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza A, Abid M, Hong S, Majhail N, Kharfan-Dabaja M, Khurana A, Badar T, Lin Y, Bennani N, Herr M, Hu Z, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini M. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood 2024, 143: 2722-2734. PMID: 38635762, PMCID: PMC11251200, DOI: 10.1182/blood.2023023447.Peer-Reviewed Original ResearchChimeric antigen receptorR/R LBCLNH-White patientsAxicabtagene ciloleucelZUMA-1ZUMA-7Autologous anti-CD19 chimeric antigen receptorCenter for International Blood and Marrow Transplant Research databaseAnti-CD19 chimeric antigen receptorHazard ratioOdds ratioLarge B-cell lymphomaProgression-free survivalT-cell therapyDuration of responseB-cell lymphomaCytokine release syndromeNH WhitesNH Black patientsAdjusted odds ratiosClinical trial settingClinical trial outcomesOverall survivalT cellsLBCLReal World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
Akhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.Peer-Reviewed Original ResearchCytokine-release syndromeProgression-free survivalTreatment-related mortalityClinically significant infectionsRelapse/refractory multiple myelomaOverall survivalIde-celProlonged cytopeniasMultiple myelomaBaseline characteristicsAnti-BCMA CAR-T cell therapyHematopoietic cell transplant-specific comorbidity indexFrail patientsComorbidity indexHigh-grade adverse eventsCAR-T cell therapyRates of overall responseNon-frail patientsRate of neurotoxicityClinically important subgroupsCharlson Comorbidity IndexAge cut-offAnti-BCMAHCT-CIComplete response
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphomaCAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsReal World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response ratePost-transplantation cyclophosphamide is associated with increased bacterial infections
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, Cerny J, Gowda L, Hill J, Liu H, Munshi P, Nathan S, Seftel M, Wingard J, Chemaly R, Dandoy C, Perales M, Riches M, Papanicolaou G. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplantation 2023, 59: 76-84. PMID: 37903992, PMCID: PMC11164622, DOI: 10.1038/s41409-023-02131-z.Peer-Reviewed Original ResearchConceptsPost-transplant cyclophosphamideHematopoietic cell transplantationBacterial infectionsMost bacterial infectionsGVHD prophylaxisInfection cohortHost diseaseCalcineurin inhibitorsMyelodysplastic syndromeCell transplantationAcute leukemiaMore infectionsDay 180Greater incidencePatientsInfectionCohortProphylaxisCyclophosphamideTransplantationSyndromeGraftLeukemiaMortalityIncidenceMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.Peer-Reviewed Original ResearchImpact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Ragon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Al Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.Peer-Reviewed Original ResearchConceptsSecond hematological malignanciesSecond primary malignanciesProgression-free survivalMultiple myelomaOverall survivalMaintenance therapyDevelopment of SPMsRisk of SPMAutologous hematopoietic stem cell transplantationInferior progression-free survivalHematopoietic stem cell transplantationHigh-dose melphalanMelphalan conditioning regimenSubsequent maintenance therapyStem cell transplantationFrequent primary causeCIBMTR analysisLenalidomide maintenanceAuto-HSCTConditioning regimenMedian survivalPrimary malignancyAdult patientsCell transplantationClinical trialsMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversityCorrection to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. Leukemia 2023, 37: 1173-1173. PMID: 36949156, DOI: 10.1038/s41375-023-01814-2.Peer-Reviewed Original ResearchCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspectiveAssociation of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia
Murthy S, Logan B, Bo‐Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared J, Stefanski H, Pulsipher M, Hsu J, Switzer G, Panch S, Shaw B. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal Of Hematology 2023, 98: 608-619. PMID: 36606713, PMCID: PMC10290878, DOI: 10.1002/ajh.26834.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMajor ABO mismatchABO mismatchHematopoietic cell transplantationAllo-HCTAcute lymphoblastic leukemiaABO statusAcute leukemiaCell transplantationMarrow Transplant Research databaseAllogeneic hematopoietic cell transplantationBidirectional ABO mismatchDonor-recipient ABOMinor ABO mismatchNon-relapse mortalityOlder recipient agePrimary graft failurePost-transplantation outcomesWorse overall survivalDonor selection algorithmsAcute graftChronic GVHDEligible patientsHost diseasePlatelet engraftment
2022
Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel
Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.Peer-Reviewed Original ResearchImpact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
Mirza A, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Ahmed S, Hematti P, Turtle C, Pasquini M, Gowda L. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). Blood 2022, 140: 4633-4635. DOI: 10.1182/blood-2022-163750.Peer-Reviewed Original ResearchImpact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia 2022, 37: 1006-1017. PMID: 36310182, PMCID: PMC10148918, DOI: 10.1038/s41375-022-01738-3.Peer-Reviewed Original ResearchConceptsPrimary induction failureAllo-HCTRIC allo-HCTComplete remissionOverall survivalConsolidation therapyAML patientsDetectable MRDRelapse riskInduction cyclesAllogeneic hematopoietic cell transplantationConsolidation cyclesPre-transplant inductionFirst complete remissionAdult AML patientsReduced-intensity conditioningBetter overall survivalHematopoietic cell transplantationRisk of relapseAllogeneic transplant outcomesCIBMTR analysisImproved OSInduction failureTransplant outcomesCell transplantationEsophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans Superficialis
Ogurick A, Liu C, Gowda L, Li D. Esophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans Superficialis. ACG Case Reports Journal 2022, 9: e00833. DOI: 10.14309/crj.0000000000000833.Peer-Reviewed Original Research